Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) AI Stock Analysis

• Market Cap: HK$6.40B
• Dividend Yield: N/A
• Average Volume (3M): 313.75K
• Price to Earnings (P/E): 174.2
• Beta (1Y): 1.25
• Revenue Growth: 34.39%
• EPS Growth: N/A
• Country: HK
• Employees: 1,117
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): 0.09
• Shares Outstanding: 110,781,920
• 10 Day Avg. Volume: 215,050
• 30 Day Avg. Volume: 313,747
• PEG Ratio: -1.40
• Price to Book (P/B): 6.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -115.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: HK$16.00 ▼( -0.50% Downside)

The overall stock score is primarily influenced by robust financial performance, with significant revenue and cash flow improvements. However, the company's high P/E ratio suggests overvaluation, and technical indicators imply the stock is currently overbought. These factors collectively suggest cautious optimism, with a focus on monitoring valuation and technical signals.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) is a Beijing-based biotechnology company operating within the pharmaceutical and healthcare sectors. The company focuses on the development of innovative biologics, leveraging advanced gene-editing technologies to create genetically engineered animal models for drug discovery and development. Biocytogen aims to accelerate the process of pharmaceutical research and development by providing high-quality preclinical models and contract research services to the global life sciences industry.

How the Company Makes Money

Biocytogen Pharmaceuticals generates revenue primarily through its contract research services and the development of genetically engineered animal models, which are crucial for drug discovery and development. The company collaborates with pharmaceutical and biotechnology companies, providing them with customized models that aid in the research and testing of new drugs. Additionally, Biocytogen enters into partnerships and licensing agreements to leverage its expertise in gene-editing technologies, further expanding its revenue streams. These collaborations and agreements often involve milestone payments and royalties, which contribute significantly to the company's earnings.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
800.58M	716.91M	533.88M	354.56M	253.54M
	Gross Profit
586.58M	506.03M	391.75M	247.44M	166.99M
	EBIT
-119.16M	-270.29M	-606.00M	-525.45M	-380.26M
	EBITDA
13.56M	-97.87M	-413.31M	-378.12M	-318.44M
	Net Income Common Stockholders
-243.82M	-382.95M	-602.16M	-585.60M	-542.97M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
957.41M	434.04M	611.27M	566.45M	950.04M
	Total Assets
0.00	2.45B	2.80B	2.30B	2.33B
	Total Debt
0.00	544.11M	415.28M	538.35M	463.80M
	Net Debt
957.41M	144.51M	-187.79M	71.91M	-286.25M
	Total Liabilities
0.00	1.66B	1.65B	1.05B	868.28M
	Stockholders Equity
1.46B	785.89M	1.15B	1.25B	1.45B
Cash Flow		Free Cash Flow
-88.28M	-203.26M	-543.94M	-564.45M	-531.73M
	Operating Cash Flow
-29.47M	-76.65M	-303.27M	-365.78M	-225.31M
	Investing Cash Flow
-42.23M	-100.28M	-153.74M	-84.13M	-188.18M
	Financing Cash Flow
-72.80M	-37.82M	587.20M	219.44M	868.44M

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2315, the sentiment is Positive. The current price of 16.08 is above the 20-day moving average (MA) of 12.34, above the 50-day MA of 13.18, and above the 200-day MA of 8.60, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 67.23 is Neutral, neither overbought nor oversold. The STOCH value of 95.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2315.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2269	78 Outperform	$96.93B	26.90	8.17%	―	7.52%	-1.92%
1093	76 Outperform	$76.12B	16.56	13.20%	4.63%	-9.60%	-27.18%
1177	66 Neutral	$74.80B	39.40	6.14%	1.44%	7.63%	-24.23%
2196	65 Neutral	$63.02B	12.72	6.22%	1.95%	-2.82%	11.93%
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
2315	51 Neutral	HK$6.40B	174.21	4.16%	―	34.39%	―

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events

Biocytogen Pharmaceuticals Announces 2024 AGM and Key Resolutions

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced the schedule for its 2024 Annual General Meeting, set for May 28, 2025, which will be held both physically and virtually. The meeting will address key resolutions including the approval of the 2024 annual report, financial statements, and remuneration plans for directors and supervisors. Additionally, a special resolution will be considered regarding the repurchase of H Shares, reflecting the company’s strategic financial management and commitment to shareholder value.

Biocytogen Pharmaceuticals Reports Strong Financial Turnaround in 2024

Biocytogen Pharmaceuticals has announced its audited consolidated annual results for the year ended December 31, 2024, showing a significant financial turnaround. The company reported a 36.8% increase in revenue and a substantial improvement in profitability, with a profit of RMB 33,537,000 compared to a loss in the previous year. This positive financial performance reflects the company’s effective cost management and operational strategies, positioning it favorably in the pharmaceutical industry and potentially benefiting its stakeholders.

Biocytogen Pharmaceuticals Schedules Board Meeting to Review Annual Results

Biocytogen Pharmaceuticals has announced a board meeting scheduled for March 26, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the payment of a final dividend, which could impact shareholder returns and reflect the company’s financial health.

Biocytogen Enhances Antibody Drug R&D with AI Integration

Biocytogen Pharmaceuticals has successfully integrated its AI-driven DeepSeek platform with its Project Integrum, marking a significant advancement in antibody drug R&D. This integration allows for more accurate and rapid development of innovative antibody drugs, enhancing the company’s ability to meet clinical needs and strengthening its position in the global pharmaceutical market.